330 related articles for article (PubMed ID: 28077299)
1. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
Roskoski R
Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299
[TBL] [Abstract][Full Text] [Related]
2. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.
Iams WT; Lovly CM
Cancer J; 2015; 21(5):378-82. PubMed ID: 26389762
[TBL] [Abstract][Full Text] [Related]
3. Insight into resistance mechanism of anaplastic lymphoma kinase to alectinib and JH-VIII-157-02 caused by G1202R solvent front mutation.
Wang H; Wang Y; Guo W; Du B; Huang X; Wu R; Yang B; Lin X; Wu Y
Drug Des Devel Ther; 2018; 12():1183-1193. PubMed ID: 29785088
[TBL] [Abstract][Full Text] [Related]
4. [Recommendations from Experts in the Management of Adverse Reactions
to ALK Inhibitors (2021 Version)].
Wang K; Li J; Sun J; Li L; Zhang X; Zhang J; Yu M; Ye X; Zhang M; Zhang Y; Yao W; Huang M
Zhongguo Fei Ai Za Zhi; 2021 Dec; 24(12):815-828. PubMed ID: 34670356
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib.
Prokoph N; Matthews JD; Trigg RM; Montes-Mojarro IA; Burke GAA; Fend F; Merkel O; Kenner L; Geoerger B; Johnston R; Murray MJ; Riguad C; Brugières L; Turner SD
Br J Haematol; 2023 Sep; 202(5):985-994. PubMed ID: 37357529
[TBL] [Abstract][Full Text] [Related]
6. The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.
Gristina V; La Mantia M; Iacono F; Galvano A; Russo A; Bazan V
Pharmaceuticals (Basel); 2020 Dec; 13(12):. PubMed ID: 33352844
[TBL] [Abstract][Full Text] [Related]
7. Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.
Liao BC; Lin CC; Shih JY; Yang JC
Ther Adv Med Oncol; 2015 Sep; 7(5):274-90. PubMed ID: 26327925
[TBL] [Abstract][Full Text] [Related]
8. Current and future treatment of anaplastic lymphoma kinase-rearranged cancer.
Mologni L
World J Clin Oncol; 2015 Oct; 6(5):104-8. PubMed ID: 26468446
[TBL] [Abstract][Full Text] [Related]
9. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.
Sullivan I; Planchard D
Ther Adv Med Oncol; 2016 Jan; 8(1):32-47. PubMed ID: 26753004
[TBL] [Abstract][Full Text] [Related]
10. Case Report:
Wen Z; Xiong D; Zhang S; Liu J; Li B; Li R; Zhang H
Front Oncol; 2021; 11():645370. PubMed ID: 33692962
[TBL] [Abstract][Full Text] [Related]
11. Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond.
Kanaan Z; Kloecker GH; Paintal A; Perez CA
Onco Targets Ther; 2015; 8():885-92. PubMed ID: 25945060
[TBL] [Abstract][Full Text] [Related]
12. Anaplastic lymphoma kinase (
Berghmans T; Remmelink M; Awada A
Lung Cancer (Auckl); 2012; 3():91-99. PubMed ID: 28210128
[TBL] [Abstract][Full Text] [Related]
13. Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer.
Nakamichi S; Seike M; Miyanaga A; Chiba M; Zou F; Takahashi A; Ishikawa A; Kunugi S; Noro R; Kubota K; Gemma A
Oncotarget; 2018 Jun; 9(43):27242-27255. PubMed ID: 29930762
[TBL] [Abstract][Full Text] [Related]
14. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.
Yuan Y; Liao YM; Hsueh CT; Mirshahidi HR
J Hematol Oncol; 2011 Apr; 4():16. PubMed ID: 21504625
[TBL] [Abstract][Full Text] [Related]
15. Rapid response to fifth-line brigatinib plus entrectinib in an
Li D; Zhu Y; Song J; Yang D; Cui S; Liu X; Wang L; Zhang J; Pan E; Dai Z
Front Oncol; 2024; 14():1339511. PubMed ID: 38699646
[TBL] [Abstract][Full Text] [Related]
16. Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.
Sharma GG; Mota I; Mologni L; Patrucco E; Gambacorti-Passerini C; Chiarle R
Cancers (Basel); 2018 Feb; 10(3):. PubMed ID: 29495603
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer.
Ramshankar V; Yegnaswamy S; P K; Arvind K
Bioinformation; 2014; 10(10):658-63. PubMed ID: 25489176
[TBL] [Abstract][Full Text] [Related]
18. Superparamagnetic Iron Oxide Nanoparticles Reprogram the Tumor Microenvironment and Reduce Lung Cancer Regrowth after Crizotinib Treatment.
Horvat NK; Chocarro S; Marques O; Bauer TA; Qiu R; Diaz-Jimenez A; Helm B; Chen Y; Sawall S; Sparla R; Su L; Klingmüller U; Barz M; Hentze MW; Sotillo R; Muckenthaler MU
ACS Nano; 2024 Apr; 18(17):11025-11041. PubMed ID: 38626916
[TBL] [Abstract][Full Text] [Related]
19. A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations.
Balasundaram A; Doss GPC
Front Mol Biosci; 2023; 10():1306046. PubMed ID: 38274094
[No Abstract] [Full Text] [Related]
20. Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase.
Liang S; Wang Q; Qi X; Liu Y; Li G; Lu S; Mou L; Chen X
Front Cell Dev Biol; 2021; 9():808864. PubMed ID: 35004700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
